The efficacy and safety of lignocaine-embedded dissolvable microneedle versus EMLA for topical analgesia in adults undergoing venepuncture: A single-centre, parallel-group, double-blind randomised clinical trial protocol in a tertiary care setting
PLOS One · 2025
DOI: 10.1371/journal.pone.0335932 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Muhammad Irfan Abdul Jalal und 15 weiteren Autor:innen. Beteiligte Einrichtung: UKM Medical Molecular Biology Institute (UMBI), Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Analgesia, Anesthetics, Local, Lidocaine, Phlebotomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology Development Fund 2 (TED2), Malaysian Ministry of Science, Technology and Innovation, Universiti Kebangsaan Malaysia Faculty of Medicine Grant.
Abstract (Originalsprache)
Venepuncture-associated pain is a major source of distress commonly experienced by adult patients in day-to-day clinical practice. Topical lignocaine application before venepuncture may address this issue, but this delivery approach may be suboptimal. Hence, we aim to investigate the safety and efficacy of a novel lignocaine-embedded transdermal microneedle array patch (LEMAP) in facilitating transcutaneous lignocaine delivery to reduce procedural-related pain in adults undergoing venepuncture in a tertiary-care outpatient clinic setting. This is an investigator-initiated, single-centre, active-controlled, double-blind, randomised superiority trial divided into two distinct stages. Twenty (single-group LEMAP recipients) and 144 adult patients (72 per group; randomised to either LEMAP (intervention) or 5% EMLA patch (control) applied on antecubital fossa, near the venepuncture site, for 30 minutes) aged 18 years and above requiring routine venepuncture will be recruited from the Ophthalmology Outpatient Clinic, Hospital Canselor Tuanku Muhriz, for stage I and II of this trial, respectively. For the stage I trial, the safety endpoints are lignocaine’s pharmacokinetic parameters and clinical adverse events. In the stage II trial, the primary endpoints are the venepuncture-associated pain experience, which will be evaluated using the Visual Analogue Scale (VAS) and the skin conductance algesimeter index (SCAI) scores at one-minute post-venepuncture. Non-linear mixed-effect model and multiple linear regression will be used to analyse the stage I and II trial outcomes, respectively. The trial protocol has been registered with the clinicaltrial.gov registry (ID: NCT05694858) and adheres to the SPIRIT 2025 reporting guideline. All trial participants will provide written informed consent, which the trial investigators will obtain before trial enrollment and randomisation. The trial findings will be disseminated via peer-reviewed publications and presentations at international conferences and shared with participants via the web-based trial notification system..
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UKM Medical Molecular Biology Institute (UMBI), Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
- Department of Ophthalmology, Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
- Department of Pharmacy, Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
- Department of Diagnostic Laboratory Services, Hospital Canselor Tuanku Muhriz (HCTM), Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
- Toxicology Division, Forensic Science Analysis Centre, Department of Chemistry Malaysia (KIMIA Malaysia), Selangor, Malaysia.
- Institute of Microengineering and Nanoelectronics (IMEN), Level 4, Research Complex, Universiti Kebangsaan Malaysia (UKM), Selangor, Malaysia.
ORCID-Profile: Muhammad Irfan Abdul Jalal, Sharmilah Kuppusami, Fook-Choe Cheah
Förderung
- Technology Development Fund 2 (TED2), Malaysian Ministry of Science, Technology and Innovation
- Universiti Kebangsaan Malaysia Faculty of Medicine Grant
Zitieren
APA
Abdul Jalal, M. I., Yen, M. Y., Chenshen, L., Bastion, M. C., Yun, C. X., Abdul Razak, S. S., Kuppusami, S., Abdul Rahman, A. S., Azizol Nashriby, M. E., Rahim, N. A. A., Ooi, P. C., Buyong, M. R., Mohamed, M. A., Dee, C. F., Hamzah, A. A., & Cheah, F. C. (2025). The efficacy and safety of lignocaine-embedded dissolvable microneedle versus EMLA for topical analgesia in adults undergoing venepuncture: A single-centre, parallel-group, double-blind randomised clinical trial protocol in a tertiary care setting. PLOS One. https://doi.org/10.1371/journal.pone.0335932
Vancouver
Abdul Jalal MI, Yen MY, Chenshen L, Bastion MC, Yun CX, Abdul Razak SS, et al. The efficacy and safety of lignocaine-embedded dissolvable microneedle versus EMLA for topical analgesia in adults undergoing venepuncture: A single-centre, parallel-group, double-blind randomised clinical trial protocol in a tertiary care setting. PLOS One. 2025. doi:10.1371/journal.pone.0335932
BibTeX
@article{AbdulJalal2025,
author = {Abdul Jalal, Muhammad Irfan and Yen, Mun Yin and Chenshen, Lam and Bastion, Mae-Lynn Catherine and Yun, Chua Xin and Abdul Razak, Sharipah Salwa and Kuppusami, Sharmilah and Abdul Rahman, Arifah Syahirah and Azizol Nashriby, Mohd Eusoff and Rahim, Nurul Ashikin A and Ooi, Poh Choon and Buyong, Muhamad Ramdzan and Mohamed, Mohd Ambri and Dee, Chang Fu and Hamzah, Azlan Azrul and Cheah, Fook-Choe},
title = {The efficacy and safety of lignocaine-embedded dissolvable microneedle versus EMLA for topical analgesia in adults undergoing venepuncture: A single-centre, parallel-group, double-blind randomised clinical trial protocol in a tertiary care setting},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0335932}
}
EUVIMED